Slide 1: Evgen Pharma plc Interim Results
EVGEN PHARMA PLC Interim results for the six months ended 30 September 2015 Investor Presentation Stephen Franklin PhD, CEO Barry Clare, Chairman John Bradshaw, CFO December 2015
Slide 2: Disclaimer
Disclaimer This document is an investor presentation which has been prepared by, and is the sole responsibility of Evgen Pharma plc (the "Company”) which trades on the AIM market of the London Stock Exchange under ticker EVG. The information in this document is subject to updating, completion, revis
Slide 3: Highlights in the year to date
Highlights in the year to date • £7 million placing and admission to AIM on 21 October 2015 • Positive data on SFX-01 as adjunct to hormonal therapy in patient-derived xenografts using cancer tissues from early and late stage breast cancer patients (data presented at the American Association of Canc
Slide 4: Company Snapshot
Company Snapshot Clinical stage drug development company focused on oncology & neurology Capital efficient & highly experienced management team Sulforaphane has established anti-cancer & neuroprotectant properties but clinical & commercial development has, to date, been precluded by the instab
Slide 5: Board of Directors
Board of Directors Barry Clare Dr Stephen Franklin John Bradshaw Dr Sue Foden Executive Chairman CEO Finance Director Non-Executive Director Former main Board member of Founder of Evgen Pharma. Trained with Arthur Andersen Former Investment Director Boots Company plc and Former CEO of Provexis plc a
Slide 6: Technology
TECHNOLOGY 6
Slide 7: Growth in Sulforaphane Science
Growth in Sulforaphane Science Sulforaphane has a large body of peer-reviewed scientific publications demonstrating effects in tumour initiation, promotion and progression (See Appendices) Shown to reduce proliferation and induce programmed cell death in many cancers and some haematological mali
Slide 8: Mechanistic studies of sulforaphane: Nrf2 and NF-kB
Mechanistic studies have largely focused on sulforaphane as a modulator of Nrf2 & NF-kB Protection against oxidative stress SF (neuroprotection, inflammation, cancer) SF Activates major Inhibits major antioxidant transcription “stress sensor” pro-inflammatory factor, Nrf2 protein Keap1 transcription
Slide 9: Sulforadex
SFX-01 Sulforadex® H2O2 H2O α-cyclodextrin α-cyclodextrin Erucin Sulforaphane Pure sulforaphane is a liquid that requires storage at minus 20oC to maintain stability, and therefore clinical trials have been precluded Sulforadex® technology enables scalable manufacturing of a synthetic sulforapha
Slide 10: Intellectual Property
Intellectual Property Stabilised sulforaphane (compositional IP): patents, applications and know-how licensed exclusively from US partner. Granted in US, Canada, Australia. Pending in Europe & Japan. Expiry 2028 Stabilised sulforaphane (process IP): two further applications awaiting internationa
Slide 11: Product Pipeline & Markets
PRODUCT PIPELINE & MARKETS 11
Slide 12: Pipeline Chart and Clinical Centres
Pipeline Chart and Clinical Centres Drug Indication 2016 2017 SFX-01 Metastatic Breast Cancer Phase I SFX-01 Subarachnoid Haemorrhage Phase II SFX-01 Multiple Sclerosis Preclinical Studies 12
Slide 13: Preclinical Collaborations
Preclinical Collaborations Start of Institution Objective collaboration 2012 Paterson Institute for Cancer Research, In vitro and in vivo effects of SFX-01 on breast cancer stem cells and mechanism of Manchester, UK action 2013 Baylor College of Medicine, Texas In vitro and in vivo effects of SFX-01
Slide 14: SFX-01: Breast Cancer
SFX-01: Breast Cancer Biggest cause of cancer death in women – over 1.5 million diagnoses annually worldwide with a therapeutic market worth US$9.2 billion in 2013 Approximately 75% of breast cancers express the estrogen receptor (ER+) and in the metastatic setting, endocrine therapy is the main
Slide 15: SFX-01: Subarachnoid Haemorrhage (SAH)
SFX-01: Subarachnoid Haemorrhage (SAH) SAH, a form of haemorrhagic stroke, accounts for 5% of strokes in the UK Treatment eligible for orphan status in the USA and Europe SAH has a fatality rate of around 50% with almost half of survivors left with cognitive impairment Aimed at reducing earl
Slide 16: SFX-01: Multiple Sclerosis
SFX-01: Multiple Sclerosis SFX-01 shares part of its mechanism of action with Biogen’s Tecfidera® Sulforaphane, the active ingredient in SFX-01, is a more potent Nrf2 activator (in-vitro) than dimethyl fumarate (see below), the active ingredient in Tecfidera® Head-to-head preclinical studies (
Slide 17: Financial Results
FINANCIAL RESULTS for the six months ended 30 September 2015
Slide 18: Financial Highlights
Financial Highlights Results for the six months ended 30 September 2015, pre admission to AIM Loss for the period was £1.2m (30 September 2014: loss £1.1m) The cash position at 30 September 2015 was £1.8m (30 September 2014: £0.2m), reflecting a £2.0m pre-IPO fundraising in August 2015 The I
Slide 19: Use of IPO proceeds
Use of IPO proceeds IPO raised £7 million gross Use of net proceeds: - Phase IIa clinical trial on SFX-01 in metastatic breast cancer; - Phase II clinical trial on SFX-01 in subarachnoid haemorrhage; - long-term safety and toxicology studies on SFX-01; - preclinical studies on SFX-01 in models o
Slide 20: Summary
SUMMARY 20
Slide 21: Summary
Summary Evgen Pharma can unlock the the therapeutic potential of sulforaphane in multiple indications The Sulforadex® opportunity has attracted a highly experienced management team operating a capital efficient business model Lead compound SFX-01 is Phase II ready and IPO funding will traverse
Slide 22: Appendices
APPENDICES 22
Slide 23: Corporate History
Corporate History 2013 2015 Secured option to in- Breast cancer data 2011 license new sulforaphane presented at the AACR in 2008-2009 analogues from Spanish Series A-led by North Philadelphia Research Council and Global search-and- West Fund for University of Seville Breast cancer Phase II screen fo
Slide 24: Sulforaphane in animal models of cancer
Sulforaphane in animal models of cancer Indication Animal Route Dose ¶ Author Main findings Breast cancer NOD-SCID gamma Oral (qd) 6.5 µmol Evgen Report Abrogates tamoxifen-induced cancer (NSG) mouse (Human (∼46mg/kg) EVG009/14 stem cell enrichment derived tumour tissue sulforaphane (2014) xenograft
Slide 25: Sulforaphane in animal models of cancer (continued)
Sulforaphane in animal models of cancer (continued) Indication Animal Route Dose ¶ Author Main findings Lung cancer K-rasLSL-G12D mice Intraperiotoneal & 6µmol Kombairaju et al No increase in tumour growth subcutaneous (∼40mg/kg) (2011) (5x week) Barrett SCID mice (FLO- Subcutaneous 4.2µmol Qazi et
Slide 26: Sulforaphane in animal models of neuroprotection
Sulforaphane in animal models of neuroprotection Indication Animal Route Dose¶ Author Main findings Alzheimer’s Disease AD-like Kunming Oral (qd) 3.5µmol Zhang et al Reduced neuronal loss and increased mice (∼25mg/kg) (2014) cognitive function Parkinson’s Disease C57BL/6 male mice Intraperitoneal ∼0
Slide 27: Sulforaphane in animal models of inflammation
Sulforaphane in animal models of inflammation Indication Animal Route Dose¶ Author Main findings Retinal Male Sprague-Dawley rats Intraperitoneal(qd) 21µmol Pan et al Increase in Nrf2 and HO-1 inflammation (12.5mg/kg) (2014) expression Osteoarthritis C57BL/6 mice Oral (diet) 3µmol Davidson et al Red
Slide 28: Published Phase II data using frozen botanical preparations
Published Phase II data using frozen botanical preparations Preparation Indication Subjects Dose¶ Plasma Reference Main findings Sulforaphane standardised Recurrent 20 200μmol (qd) 0.2µM Alumkal et al Significant lengthening of the broccoli sprout extract (frozen) Prostate Cancer (0.5mg/kg) (2014) P
Slide 29: Clin Cancer Research 2010; 16(9): 2580-2590
Clin Cancer Research 2010; 16(9): 2580-2590 29
Slide 30: Sulforadex targets breast cancer stem-like cells
increased rate of distant metastasis. All 5 cut-points with p value Distant metastasis-free 0.0 0.2 0.4 0.6 0.8 1.0 below 0.05 are indicated. Vertical bars on survival curves indicate Wnt low censored cases. The gene expression data on 164 tamoxifen- Sulforadex targets breast cancer stem-like cells
Slide 31: J Neuroscience Res 2011; 89: 515-523
J Neuroscience Res 2011; 89: 515-523 31
Slide 32: Stroke 2007; 38: 3280-3286
Stroke 2007; 38: 3280-3286 32
Slide 33: Experimental Neurology 2013; 250: 239-249
Experimental Neurology 2013; 250: 239-249 33
Slide 34: Evgen Pharma contact details
Evgen Pharma Liverpool Science Park Innovation Centre 2 146 Brownlow Hill Liverpool L3 5RF www.evgen.com 34